These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 33632095)

  • 1. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
    Xu J; Shi PY; Li H; Zhou J
    ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
    Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
    J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad-spectrum coronavirus antiviral drug discovery.
    Totura AL; Bavari S
    Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
    Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
    Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.
    Li H; Hu Y; Tang H; Li S; Ding H; Zhai S; Zhao R
    Am J Chin Med; 2020; 48(7):1539-1552. PubMed ID: 33202150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic.
    Negi M; Chawla PA; Faruk A; Chawla V
    Bioorg Chem; 2020 Nov; 104():104315. PubMed ID: 33007742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What are our pharmacotherapeutic options for MERS-CoV?
    Al-Tawfiq JA; Memish ZA
    Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
    Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
    Kandeel M; Al-Nazawi M
    Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses.
    Borbone N; Piccialli G; Roviello GN; Oliviero G
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33668428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
    Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
    Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
    Idrees M; Khan S; Memon NH; Zhang Z
    Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
    Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
    Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.